An Ebola vaccine (rVSV-ZEBOV-GP Ebola vaccine) tested in Africa is 97.5% effective. Only 8.8% (60/679) of the vaccinated rings reported Ebola cases, and only 2.2% (15/679) reported Ebola cases 10 days or more after vaccination.The majority of cases among vaccinated people (76%, 54/71) occurred among high-risk contacts. Only 2 out of 68,279 vaccinated contacts of contacts developed Ebola. This indicates that the ring vaccination has an effect in preventing tertiary generation of cases. The estimated Ebola attack rate for vaccinated individuals was about 0.017%, compared with an estimated 0.656 %in unvaccinated individuals.
Two Ebola drugs have proven so effective in a clinical trial that researchers will make the treatments available to anyone infected with the virus in the Democratic Republic of the Congo (DRC), where Ebola has killed nearly 1,900 people over the past year.
The survival rate for people who received either drug shortly after infection, when levels of the virus in their blood were low, was 90%.
e of the drugs, REGN-EB3, is a cocktail of three monoclonal antibodies against Ebola made by Regeneron Pharmaceuticals of Tarrytown, New York. The second, mAB114, is derived from a single antibody recovered from the blood of a person who survived Ebola in the DRC in 1995 , and was developed by the US National Institute of Allergy and Infectious Diseases (NIAID).
Both drugs outperformed two other experimental treatments in the unprecedented multi-drug clinical trial in the DRC, the World Health Organization, INRB and NIAID said in a joint statement on 12 August. Preliminary data from the first 499 people enrolled in the study show that 29% of people given REGN-EB3 died, compared with 34% of those who received mAb114.
By contrast, 53% of patients who received the anti-viral drug remdesivir died, as did 49% of those who received ZMapp, an antibody treatment that was tested during a major Ebola outbreak in West Africa from 2014 to 2016.